Overview

Precision Neuroscience represents a alternative approach to intracortical recording, developed by neurosurgeon Benjamin Rapoport, a co-founder and early leader at Neuralink. Founded in 2021 with $93 million in Series C funding from Founders Fund, the company is advancing a unique cortical surface array methodology.

Layer 7 Technology

The Layer 7 Cortical Interface contains 1,024 electrodes positioned on the brain’s surface rather than penetrating into cortical tissue. Individual electrodes are one-fifth the thickness of human hair, enabling high spatial resolution while remaining minimally invasive. The array is positioned directly in Layer 7 of the cortex, a superficial structure accessible without deep penetration.

Surgical Advantages

By eliminating penetrating electrodes, Precision Neuroscience reduces risks of chronic scarring, infection, and glial scar formation that affect deeper intracortical implants. The approach requires only dural incision rather than cortical penetration, potentially extending device longevity and reliability.

Regulatory Progress

Precision Neuroscience achieved FDA 510(k) clearance in April 2025, establishing the regulatory pathway for clinical trials. This clearance validates the surface-array approach as a distinct category within the BCI landscape.